$STTK

Shukla Abhinav A. sold $3K of STTK

Shukla Abhinav A. (Chief Technical Officer) sold 410 shares of Shattuck Labs, Inc. (STTK) at $7.01 on 2026-07-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Shukla Abhinav A.
Published Jul 7, 2026, 11:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 7, 2026, 11:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$STTK
Neutral
medium confidence
Mentioned
$STTK
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STTKNeutralLow
01

Why it matters

Traders may briefly reassess sentiment around STTK, but there is no accompanying operational or financial update in the text.

02

Market read

A routine 10b5-1 insider sale is disclosed; expected impact is limited and mostly sentiment-related.

03

What to watch

The filing does not disclose intent beyond the pre-arranged plan; the sale size ($2,874) is small relative to typical liquidity and is unlikely to be a fundamental signal.

Relevance 2/10Novelty 3/10Timing: Filed 2026-07-07 after-hours; reflects sale executed 2026-07-02.

Background

The article is an SEC Form 4 insider transaction: CTO Abhinav Shukla sold shares at a stated price under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$STTKNeutralMedium confidence
Context

Shattuck Labs CTO Abhinav Shukla sold 410 shares in an open-market transaction at $7.01/share under a 10b5-1 plan.

Expected impact

Likely minimal near-term impact; any move would be sentiment-driven and typically fades.

Evidence & confidence

Form 4 provides transaction mechanics (size, price, 10b5-1), but no new company performance, guidance, or regulatory/operational catalyst.

Market effects

No clear sector read-through; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still be viewed as a bearish signal by some traders.

Key entities

  • Shattuck Labs, Inc.

    Company whose insider sale is disclosed via Form 4.

  • Abhinav Shukla

    Chief Technical Officer who executed the open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$STTKMed

Strattec Security Corporation Q4 2026 Earnings Call Summary

Strattec Security Corporation reported record annual revenue of $579.4 million for 2026, driven by pricing, cost actions, and operational improvements. The company reorganized its product portfolio and realized $6 million in restructuring savings, expanding gross margin to 16.5%. Strattec anticipates a challenging 2027 with a 2% decline in North American production and targets long-term gross margins of 18% to 20%. The company maintains a debt-free balance sheet with $108.2 million in cash and p

$STTKMed

Shattuck Labs Jumps as Two Analysts Start Bullish Coverage

Shattuck Labs (STTK) rose 4.91% after two analysts initiated coverage with positive ratings. TD Cowen rated it buy, while Raymond James gave a strong buy and $18 price target. Both highlighted SL-325, a drug candidate for inflammatory bowel disease, citing its novel mechanism. The company reported $208.3M in cash and expects funding into 2029. Phase 2b trial for SL-325 is set to start in Q3.

$STTKMed

H.C. Wainwright cuts Shattuck Labs stock price target on trial expansion

H.C. Wainwright cut its price target for Shattuck Labs (NASDAQ:STTK) to $14 from $18 while keeping a Buy rating, after Shattuck reported Q2 2026 results on Aug. 11. Shattuck expanded its RECEPTIVE-CD1 Phase 2b trial to three doses and ~232 patients. The SL-325 Crohn’s trial remains on track for a Q3 2026 start. The article also notes a $75M public offering and warrant exercises.

$STTKMed

Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent

Shattuck Labs, Inc. (STTK) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights – Phase 1 clinical trial results for SL-325 demonstrated a favorable safety profile, a potentially best-in-mechanism immunogenicity profile, and durable DR3 blockade of TL1A bi